Purchase this article with an account.
Saba abdulmohsen Alreshaid; Comparison of surgery, intravitreal ocriplasmin and observation in symtomatic vitreomacular traction syndrome. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1225.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compares the effects of pars plana vitrectomy and intravitreal injection of ocriplasmin with observation in symtpmatic VMT
retrospective study of patients who had symtomatic VMT . VMT was diagnosed by spectral domain optical coherence tomography . Main outcome measures included best-corrected visual acuity and VMT status (released vs not released) at baseline and the last follow-up.
Total of 51 eyes of 50 patients. 11 eyes in surgical group , 8 eyes in ocriplasmin group and 32 eyes in observation group. The mean ± SD follow up in surgical, ocriplasmin and observation groups were 10.27 ± 4.63 months, 3.87 ± 2.66 months and 6.27 ± 2.29 months, respectively. Baseline visual acuity (logMAR) in surgical, ocriplasmin and observation groups was 0.81 ± 0.24 (Snellen equivalent 20/125), 0.53 ± 0.29 (20/70) and 0.58 ± 0.25 (20/70), respectively. Visual acuity (logMAR) at the last visit in surgical, ocriplasmin and observation groups was 0.64 ± 0.26 (20/80), 0.52 ± 0.29 (20/70) and 0.57 ± 0.28 (20/70), respectively. The change in visual acuity between baseline and the last visit was significant in the surgical group (p=0.041) and was non-significant in the ocriplasmin (p=0.40) and observation (p=0.62) groups. At the last visit, VMT was released in all eyes (100%) in the surgical group, in 5 of 8 eyes (62.5%) in the ocriplasmin group and in 10 of 32 eyes (31.2%) in the observation group and was statistically significant in VMT release between surgery vs observation (P=0.00008) and surgery vs ocriplasmin (p=0.027) however was not sginificant between ocriplasmin and observation (p=0.1031). one case had lamellar hole after surgery, worsening of BCVA in one case after ocriplasmin injection and two in the observation group.
Surgical intervention results in complete release of VMT with improvement in visual acuity. Intravitreal pharmacotherapy and observation have similar rates of VMT release with little change in visual acuity
This PDF is available to Subscribers Only